Induction of chimerism in rhesus macaques through stem cell transplant and costimulation blockade-based immunosuppression

American Journal of Transplantation

Volumn 7, Issue 2, 2007, Pages 320-335

  Kean, L S ^a,b   Adams, A B ^a   Strobert, E ^c   Hendrix, R ^a   Gangappa, S ^a   Jones, T R ^a   Shirasugi, N ^a   Rigby, M R ^a,b   Hamby, K ^a   Jiang, J ^a   Bello, H ^a   Anderson, D ^c   Cardona, K ^a   Durham, M M ^a   Pearson, T C ^a   Larsen, C P ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Chimerism; Costimulation; Non human primate; Nonmyeloablative; Tolerance; Transplant

Indexed keywords

15 DEOXYSPERGUALIN; BASILIXIMAB; BELATACEPT; BUSULFAN; CIDOFOVIR; CITRATE SODIUM; DOPAMINE; GANCICLOVIR; GLUCONATE CALCIUM; GRANULOCYTE COLONY STIMULATING FACTOR; LF 15 0195; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H 106; RAPAMYCIN; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD DONOR; BONE MARROW; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; CHIMERA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; GRAFT REJECTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HYPOTENSION; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; LEUKAPHERESIS; MACACA; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE; THYMECTOMY; TRANSPLANTATION TOLERANCE; TREATMENT DURATION; VIRUS REACTIVATION;

ANIMALS; BONE MARROW TRANSPLANTATION; BUSULFAN; CHIMERISM; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LEUKAPHERESIS; MACACA MULATTA; RECEPTORS, INTERLEUKIN-2; SIROLIMUS; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE;

EID: 33846217342     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01622.x     Document Type: Article

References (80)

1. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168-170.
2. Zinkernagel RM. Thymus function and reconstitution of immunodeficiency. N Engl J Med 1978; 298: 222.
3. Zinkernagel RM, Althage A, Waterfield E et al. Restriction specificities, alloreactivity, and allotolerance expressed by T cells from nude mice reconstituted with H-2-compatible or -incompatible thymus grafts. J Exp Med 1980; 151: 376-399.
4. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001; 14: 417-424.
5. Sharabi Y, Sachs DH. Engraftment of allogeneic bone marrow following administration of anti-T cell monoclonal antibodies and low-dose irradiation. Transplant Proc 1989; 21: 233-235.
6. Wekerle T, Sayegh MH, Hill J et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998; 187: 2037-2044.
7. Adams AB, Durham MM, Kean L et al. Costimulation blockade, busulfan, and bone marrow promote titratable macro-chimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001; 167: 1103-1111.
8. Wekerle T, Sykes M. Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation 1999; 68: 459-467.
9. Wekerle T, Sachs DH, Sykes M. Mixed chimerism for the induction of tolerance: potential applicability in clinical composite tissue grafting. Transplant Proc 1998; 30: 2708-2710.
10. Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 1994; 153: 1087-1098.
11. Durham MM, Bingaman AW, Adams AB et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 1-4.
12. Kawai T, Sogawa H, Koulmanda M et al. Long-term islet allograft function in the absence of chronic immunosuppression: a case report of a nonhuman primate previously made tolerant to a renal allograft from the same donor. Transplantation 2001; 72: 351-354.
13. Kawai T, Cosimi AB, Colvin RB et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256-262.
14. Kimikawa M, Kawai T, Sachs DH, Colvin RB, Bartholomew A, Cosimi AB. Mixed chimerism and transplantation tolerance induced by a nonlethal preparative regimen in cynomolgus monkeys. Transplant Proc 1997; 29: 1218.
15. Kawai T, Poncelet A, Sachs DH et al. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation 1999; 68: 1767-1775.
16. Kawai T, Abrahamian G, Sogawa H et al. Costimulatory blockade for induction of mixed chimerism and renal allograft tolerance in nonhuman primates. Transplant Proc 2001; 33: 221-222.
17. Kawai T, Sogawa H, Boskovic S et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004; 4: 1391-1398.
18. Kimikawa M, Sachs DH, Colvin RB, Bartholomew A, Kawai T, Cosimi AB. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997; 64: 709-716.
19. Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991; 114: 954-955.
20. Buhler LH, Spitzer TR, Sykes M et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 1405-1409.
21. Fudaba Y, Spitzer TR, Shaffer J et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: In vivo and in vitro analyses. Am J Transplant 2006; 6:2121-2133.
22. Spitzer TR, Delmonico F, Tolkoff-Rubin N et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68: 480-484.
23. Kean LS, DurhamMM,Adams AB et al. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood 2002; 99: 1840-1849.
24. Kean LS, Manci EA, Perry J et al. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood 2003; 102: 4582-4593.
25. Iannone R, Luznik L, Engstrom LW et al. Effects of mixed hematopoietic chimerism in amouse model of bone marrow transplantation for sickle cell anemia. Blood 2001; 97: 3960-3965.
26. Horan JT, Liesveld JL, Fenton P, Blumberg N, Walters MC. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005; 35: 171-177.
27. Watkins DI. The evolution of major histocompatibility class I genes in primates. Crit Rev Immunol 1995; 15: 1-29.
28. Knapp LA, Lehmann E, Piekarczyk MS, Urvater JA, Watkins DI. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 1997; 50: 657-661.
29. Lobashevsky A, Smith JP, Kasten-Jolly J et al. Identification of DRB alleles in rhesus monkeys using polymerase chain reaction-sequence-specific primers (PCR-SSP) amplification. Tissue Antigens 1999; 54: 254-263.
30. Healy DL, Bacher J, Hodgen GD. A method of thymectomy in macaques. J Med Primatol 1983; 12: 89-100.
31. Lebreton L, Jost E, Carboni B et al. Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin 2. Structural modifications of the spermidine moiety. J Med Chem 1999; 42: 4749-4763.
32. Adams AB, Williams MA, Jones TR et al. Heterologous immunity provides a potent barrier to transplantation tolerance [see comment]. J Clin Inves 2003; 111: 1887-1895.
33. Vogel TU, Evans DT, Urvater JA, O'Connor DH, Hughes AL, Watkins DI. Major histocompatibility complex class I genes in primates: co-evolution with pathogens. Immunol Rev 1999; 167: 327-337.
34. Otting N, Heijmans CM, Noort RC et al. Unparalleled complexity of the MHC class I region in rhesus macaques. Proc Natl Acad Sci USA 2005; 102: 1626-1631.
35. Lobashevsky AL, Thomas JM. Six mamu-A locus alleles defined by a polymerase chain reaction sequence specific primer method. Hum Immunol 2000; 61: 1013-1020.
36. Han D, Ricordi C, Xu X, Kenyon NS. Quantitative polymerase chain reaction assessment of chimerism in non-human primates after sex-mismatched islet and bone marrow transplantation. Transplantation 2000; 69: 1717-1721.
37. Panse JP, Heimfeld S, Guthrie KA et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol 2005; 128: 659-667.
38. Baron F, Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. Mol Ther 2006; 13: 26-41.
39. Maris M, Storb R. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases. Immunol Res 2003; 28: 13-24.
40. Storb R. Non-myeloablative allogeneic transplantation - State-of-the-art. Pediatr Transplant 2004; 8(Suppl. 5): 12-18.
41. Kimikawa M, Kawai T, Sachs DH, Colvin RB, Bartholomew A, Cosimi AB. Mixed chimerism and transplantation tolerance induced by a nonlethal preparative regimen in cynomolgus monkeys. Transplant Proc 1997; 29: 1218.
42. Trambley J, Bingaman AW, Lin A et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Inves 1999; 104: 1715-1722.
43. Markees TG, Phillips NE, Gordon EJ et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998; 101: 2446-2455.
44. Xu H, Montgomery SP, Preston EH et al. Studies investigating pretransplant donor-specific blood transfusion, sirolimus, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. J Immunol 2003; 170: 2776-2782.
45. Preston EH, Xu H, Dhanireddy KK et al. IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. Am J Transplant 2005; 5: 1032-1041.
46. Thomas JM, Contreras JL, Smyth CA et al. Successful reversal of streptozotocin-induced diabetes with stable allogeneic islet function in a preclinical model of type 1 diabetes. Diabetes 2001; 50: 1227-1236.
47. Thomas JM, Contreras JL, Jiang XL et al. Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 1999; 68: 1660-1673.
48. Thomas JM, Eckhoff DE, Contreras JL et al. Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: absence of chronic allograft nephropathy. Transplantation 2000; 69: 2497-2503.
49. Contreras JL, Wang PX, Eckhoff DE et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: amatter of proinflammatory cytokine control. Transplantation 1998; 65: 1159-1169.
50. Hutchings A, Wu J, Asiedu C et al. The immune decision toward allograft tolerance in non-human primates requires early inhibition of innate immunity and induction of immune regulation. Transpl Immunol 2003; 11: 335-344.
51. Zhou D, O'Brien C, Shum J et al. LF 15-0195, a novel immunosuppressive agent prevents rejection and induces operational tolerance in a mouse cardiac allograft model. Transplantation 2003; 76: 644-650.
52. Min WP, Zhou D, Ichim TE et al. Synergistic tolerance induced by LF15-0195 and anti-CD45RB monoclonal antibody through suppressive dendritic cells. Transplantation 2003; 75: 1160-1165.
53. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-438.
54. Pearson TC, Alexander DZ, Corbascio M et al. Analysis of the B7 costimulatory pathway in allograft rejection. Transplantation 1997; 63: 1463-1469.
55. Sachs DH. Mixed chimerism as an approach to transplantation tolerance. Clin Immunol 2000; 95: S63-S68.
56. Sykes M, Ohdan H, Manilay JO, Wekerle T, Yang YG. Hematopoietic chimerism and tolerance of T cells, B cells, and NK cells. Transplant Proc 1998; 30: 4020.
57. Sykes M, Sachs DH. Mixed allogeneic chimerism as an approach to transplantation tolerance [erratum appears in Immunol Today 1988; 9(5): 131]. Immunol Today 1988; 9: 23-27.
58. Sykes M, Spitzer TR. Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies. Cancer Treat Res 2002; 110: 79-99.
59. Sayegh MH, Carpenter CB. Transplantation 50 years later-progress, challenges, and promises. N Engl J Med 2004; 351: 2761-2766.
60. Platt OS, Guinan EC. Bone marrow transplantation in sickle cell anemia - The dilemma of choice. N Engl J Med 1996; 335: 426-428.
61. Vermylen C, Cornu G, Ferster A et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22: 1-6.
62. Walters MC. Bone marrow transplantation for sickle cell disease: where do we go from here? J Pediatr Hematol Oncol 1999; 21: 467-474.
63. Walters MC, Patience M, Leisenring W et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996; 2: 100-104.
64. Walters MC, Patience M, Leisenring W et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001; 7: 665-673.
65. Buhlmann JE, Gonzalez M, Ginther B et al. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol 1999; 162: 4373-4376.
66. Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J Immunol 1997; 159: 3460-3473.
67. Adams AB, Pearson TC, Larsen CP. Conventional immunosuppression and co-stimulation blockade. Philos Trans R Soc Lond B Biol Sci 2001; 356: 703-705.
68. Adams AB, Shirasugi N, Durham MM et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002; 51: 265-270.
69. Sykes M, Szot GL, Swenson KA, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997; 3: 783-787.
70. Wekerle T, Kurtz J, Ito H et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464-469.
71. Wekerle T, Nikolic B, Pearson DA, Swenson KG, Sykes M. Minimal conditioning required in a murine model of T cell depletion, thymic irradiation and high-dose bone marrow transplantation for the induction of mixed chimerism and tolerance. Transpl Int 2002; 15: 248-253.
72. Field EH, Strober S. Tolerance, mixed chimerism and protection against graft-versus-host disease after total lymphoid irradiation. Philos Trans R Soc Lond B Biol Sci 2001; 356: 739-748.
73. Hubbard WJ, Moore JK, Contreras JL et al. Phenotypic and functional analysis of T-cell recovery after anti-CD3 immunotoxin treatment for tolerance induction in rhesus macaques. Hum Immunol 2001; 62: 479-487.
74. Thomas JM, Hubbard WJ, Sooudi SK, Thomas FT. STEALTH matters: a novel paradigm of durable primate allograft tolerance. Immunol Rev 2001; 183: 223-233.
75. Kirk AD, Mannon RB, Kleiner DE et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005; 80: 1051-1059.
76. Koehn B, Gangappa S, Miller JD, Ahmed R, Larsen CP. Patients, pathogens, and protective immunity: the relevance of virus-induced alloreactivity in transplantation. J Immunol 2006; 176: 2691-2696.
77. Williams MA, Adams AB, Walsh MB et al. Primary and secondary immunocompetence in mixed allogeneic chimeras. J Immunol 2003; 170: 2382-2389.
78. Williams MA, Onami TM, Adams AB et al. Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol 2002; 169: 5387-5391.
79. Ely LK, Green KJ, Beddoe T et al. Antagonism of antiviral and allogeneic activity of a human public CTL clonotype by a single altered peptide ligand: implications for allograft rejection. J Immunol 2005; 174: 5593-5601.
80. Forman D, Welsh RM, Markees TG et al. Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms. J Immunol 2002; 168: 6047-6056.